Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.

International journal of laboratory hematology - 1 Aug 2017

Nummi V, Jouppila A, Lassila R

Abstract excerpt

INTRODUCTION: Prophylaxis is the recommended treatment mode for severe hemophilia B. However, no single treatment regimen fits for all patients. Once-weekly prophylaxis with high-dose recombinant factor IX (rFIX) is efficacious, nevertheless, laboratory outcomes following 72 h after administration are lacking. METHODS: In a prospective open-label noncomparative study, 10 severe/moderate (FIX ≤2 IU/dL) adult...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Blood Coagulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Coagulation Tests

Share to Disease Management

Share to Factor IX

Share to Hemophilia B

Share to Recombinant Proteins

Share to Thrombin

Source

Identifiers

PMID: 28406575
DOI: 10.1111/ijlh.12634

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.PMID 28406575Read ↗

Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene ElaparvovecSemantic proximity Read ↗

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialSemantic proximity Read ↗

Hemostatic Profiling of Generic Factor Xa Inhibitors Using ROTEM® Viscoelastometry and Multimodal Coagulation Assays: A Real-World Study in a Tunisian CohortSemantic proximity Read ↗

Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.Semantic proximity Read ↗

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.Semantic proximity Read ↗

Prophylactic Therapy with Emicizumab in Patients with Hemophilia A: Benefits and ChallengesSemantic proximity Read ↗

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia ASemantic proximity Read ↗

Characterization of recombinant factor IX fusion proteins enabling subcutaneous administration.Semantic proximity Read ↗

Thrombin generation testing in haemophilia comprehensive care centres.Semantic proximity Read ↗

Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.Semantic proximity Read ↗

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia BSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.